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Abstract
Background: An altered susceptibility of lung fibroblasts to Fas-induced apoptosis has been
implicated in the pathogenesis of pulmonary fibrosis; however, the underlying mechanism is not
completely understood. Here, we studied the susceptibility of lung fibroblasts, obtained from
patients with (f-fibs) and without pulmonary fibrosis (n-fibs), to FasL- (CD95L/APO-1) induced
apoptosis in relation to the expression and the amounts of membrane-bound and soluble Fas. We
also analysed the effects of tumor necrosis factor-β  on FasL-induced cell death.
Methods:  Apoptosis was induced with recombinant human FasL, with and without prior
stimulation of the fibroblasts with tumor necrosis factor-α  and measured by a histone
fragmentation assay and flow cytometry. The expression of Fas mRNA was determined by
quantitative PCR. The expression of cell surface Fas was determined by flow cytometry, and that
of soluble Fas (sFas) was determined by enzyme-linked immunosorbent assay.
Results:  When compared to n-fibs, f-fibs were resistant to FasL-induced apoptosis, despite
significantly higher levels of Fas mRNA. F-fibs showed lower expression of surface-bound Fas but
higher levels of sFas. While TNF-α  increased the susceptibility to FasL-induced apoptosis in n-fibs,
it had no pro-apoptotic effect in f-fibs.
Conclusions: The data suggest that lower expression of surface Fas, but higher levels of apoptosis-
inhibiting sFas, contribute to the resistance of fibroblasts in lung fibrosis against apoptosis, to
increased cellularity and also to increased formation and deposition of extracellular matrix.
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Background
Lung fibrosis is the final common and often irreversible
pathway of different lung diseases, such as idiopathic
interstitial pneumonitis (idiopathic pulmonary fibrosis)
and granulomatous diseases (sarcoidosis) [1-3]. Though
these diseases are different in their etiology, all are charac-
terized by zones of lung injury where varying numbers of
fibroblasts proliferate and contribute to the accumulation
of extracellular matrix (ECM). Interstitial and intralumal
deposition of connective tissue then disrupts the lung
architecture and impairs respiratory function.
Recent studies have shown that the development of lung
fibrosis is accompanied by the differentiation of normal
lung fibroblasts into myofibroblasts. These myofibrob-
lasts express α -smooth muscle actin, and they are thought
to be the major source of collagen and profibrogenic
growth factors in the fibrosing lung [4]. Additionally,
decreased apoptosis of these cells may contribute to the
remodeling of lung tissue during chronic inflammation.
Apoptosis is a physiological process that is highly selective
in eliminating aged and injured cells. In addition to inter-
nal pathways that mainly trigger apoptosis in response to
cytotoxic stress, apoptosis can also be induced by cell-
membrane-anchored signaling pathways of the TNF-
superfamily: the CD95-receptor/CD95-ligand-system
(Fas/FasL or APO-1) and the tumor necrosis factor (TNF)-
related apoptosis inducing ligand (TRAIL or APO-2L) with
the TRAIL receptors 1 and 2 (TRAIL-R1 and R2) and the
decoy receptors DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4).
TRAIL induces programmed cell death in many tumor
cells, but not in normal, non-neoplastic cells [5].
The mechanisms through which stimulation of Fas by
FasL initiate apoptosis have been extensively investigated.
It is also known that mesenchymal, fibroblast-like cells
express Fas. Alterations in the susceptibility of these cells
to Fas-induced cell death contribute to the pathogenesis
of lung fibrosis, [6,7] and myofibroblasts are susceptible
to the suppression of apoptosis by transforming growth
factor-β 1 (TGF-β 1) [6] and resistant to interleukin (IL)-6-
induced apoptosis [8]. However, the molecular mecha-
nisms which regulate these alterations in resistance to
proapoptotic signals, and thus contribute to decreased
apoptosis of fibroblasts during chronic inflammation, are
not known in detail.
Apoptosis is regulated by a complex system consisting of
numerous proteins and cascading proteolytic and phos-
phorylation steps. The contribution of isolated elements
of the system to the regulation of apoptosis resistance is
less well characterized. The binding of soluble or cell sur-
face bound FasL with surface Fas may initiate apoptosis.
Consequently, the intensity and the stochiometry of the
Fas-FasL interaction could play a crucial role in the regula-
tion of apoptosis.
In this study we systematically investigated the expression
and interplay of the Fas/FasL system in fibroblasts
obtained from patients with and without lung fibrosis.
We aimed to clarify the possible involvement of the Fas/
FasL system in the survival of lung myofibroblasts and the
development of lung fibrosis.
Methods
Human tissues
Tissue samples from patients with (n = 5) and without
lung fibrosis (n = 6) were obtained from diagnostic open
lung biopsies (fibrotic samples) and from healthy tissue
areas during pneumonectomy for tumor resection (non-
fibrotic samples). The fibrotic samples comprised the fol-
lowing diseases: usual interstitial pneumonia (UIP, two
patients), non-specific interstitial pneumonia (NSIP, one
patient), bronchiolitis obliterans-organizing pneumonia
(BOOP, two patients) [3]. Although these diseases are dif-
ferent in clinical behavior and outcome, they are charac-
terized by increased amounts of activated fibroblasts and
increased matrix deposition. The histology of these tissue
samples was recently partially described [9]. The lung
fibroblasts were compared to synovial fibroblasts (n = 5),
which were obtained from patients with osteoarthritis
during joint replacement surgery. An experienced surgical
pathologist (C.R.) examined the tissue specimens. All tis-
sue samples were obtained immediately after surgery and
used for the isolation of fibroblasts. The tissue sampling
was approved by the local ethical committee.
Characterization of fibroblasts by flow cytometry
Fibroblasts were trypsinized. For extracellular staining,
fibroblast-specific antibodies [clones AS02 (anti-Thy-1)
and D7-Fib; Dianova, Hamburg, Germany], a macro-
phage-specific anti-CD68 (clone KP1; Signet Laboratories,
Inc., Dedham, MA) and a pan-leukocyte anti-CD45 anti-
body were used.
Cells were incubated with the primary antibodies for 30
min and with a fluorescein isothiocyanate (FITC)-labeled
goat-anti-mouse IgG for 20 min. In addition, intracellular
fluorescence staining was performed with anti-prolyl-4-
hydroxylase antibodies (clone 5B5; DPC Biermann, Bad
Nauheim, Germany) using the Fix and Perm reagent
(Dianova) according to the instructions of the manufac-
turer. For the analysis, a FACSCalibur (Becton Dickinson,
Heidelberg, Germany) flow cytometer was used.
Cell culture
Fibroblasts were obtained by mincing freshly excised lung
parenchyma into ~1 mm3 pieces, followed by digestion
with collagenase IV (1 mg/ml, Sigma, Deissenhofen,Respiratory Research 2005, 6:37 http://respiratory-research.com/content/6/1/37
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Germany) for 30 min at 37 °C. Fibroblasts were cultured
in a 75-ml tissue culture flask containing Iscove's modi-
fied Dulbecco's medium with 10% (w/v) fetal calf serum
(FCS), 10-3 M glutamine and antibiotics, at 37°C and 5%
(v/v) CO2 until they reached confluence. Only fibroblasts
between passages 3 and 8 were used for the experiments.
Determination of collagen and ECM deposition
Collagen secretion and deposition into the ECM was
assessed by proline incorporation assays originally devel-
oped by Peterovsky and Diegelmann [10] and described
in detail earlier [11,12]. All assays were performed in trip-
licate. Briefly, 5 × 104 fibroblasts were seeded into 24-well
plates (Falcon, Heidelberg, Germany) in culture medium
containing 10 % FCS. After 16 h, the medium was
changed to low serum medium (Dulbecco's modified
Eagle's medium supplemented with 0.1% FCS, 100 µg/ml
L-ascorbic acid) containing [2,3,4,5-3H]-lL-proline (2
µCi/ml, NEN, Boston, MA). When indicated, E64d was
added (10 µM). After 72 h, the culture medium was
removed and the remaining fibroblasts were lysed with
distilled water (10 min, room temperature). The ECM was
ethanol fixed (70% ethanol, 15 min, RT). Half of the wells
were incubated with 30 U/ml collagenase (Clostridium his-
tolyticum, Sigma, Deissenhofen, Germany) in collagenase
assay buffer (50 mM Tris-HCL, pH 7.5, 5 mM CaCl2, 2.5
mM N-ethylmaleimide) for 4 h at 37°C. The remaining
wells were incubated with assay buffer. The supernatants
were removed and residual ECM was solubilized by over-
night incubation in 0.3 M NaOH-1% SDS. Equal numbers
of aliquots of supernatants obtained after collagenase
digestion and supernatants containing the residual ECM
were subjected to liquid scintillation counting. The counts
measured in supernatants after collagenase treatment rep-
resent the collagen content. The amount of [3H]proline
measured after solubilization of the remaining ECM rep-
resents non-collagenous ECM. The total of both counts
was equal to the counts from solubilized ECM without
collagenase treatment and represents the total proline
incorporation. Relative ECM synthesis can be calculated
by the established formula [12]: ECM = CPM in collagen
+ (5.4 × CPM in non-collagen ECM). The formula con-
tains the factor 5.4 to correct for the 5.4-fold higher pro-
line or hydroxyproline content of collagens compared
with that of other proteins.
Induction and detection of apoptosis
Fibroblasts were stimulated with 100 ng/ml recombinant
human FasL for 16 h as described [13]. When indicated,
cells were preincubated with TNF-α  or cycloheximide
(100 µg/ml) for 24 h. Subsequently, apoptosis was deter-
mined using a histone fragmentation assay (Cell Death
Detection ELISAPlus, Roche Diagnostics, Mannheim, Ger-
many) according to the manufacturer's instructions. This
assay is based on a quantitative sandwich-enzyme-immu-
noassay using mouse monoclonal antibodies against
DNA and histones that allow for the specific, quantitative
determination of cytoplasmatic histone-associated-DNA-
fragments (mono- and oligonucleosomes) in the cell
lysates. The ELISA plates were read at 405 nm (490 nm ref-
erence). We have shown before that the results obtained
using this assay correlate to the amount of apoptotic cells
found after TUNEL staining [14].
Additionally, apoptosis was measured in lung fibroblasts
using TUNEL staining (ApoBrdU kit, Pharmingen, Heidel-
berg, Germany). Briefly, following induction of apoptosis,
cells were fixed in 1% paraformaldehyde and incubated
with Br-dUTP in the presence of TdT enzyme, which
results in the incorporation of Br-dUTP into exposed 3-
OH DNA ends. Br-dUTP sites were then labeled with
FITC-conjugated anti-Br-dUTP antibodies. The number of
apoptotic cells was measured using flow cytometry (FACS
Calibur, Becton Dickinson), and labeling with Br-dUTP
was compared with that of unstimulated controls.
Measurement of Fas/CD95 mRNA
Expression levels of Fas/CD95 mRNA were analyzed by
quantitative real time PCR using a fluorogenic 5'-nuclease
assay (TaqMan©, Applied Biosystems, Weiterstadt, Ger-
many) on a ABI Prism 7900 HT Sequence Detection sys-
tem. For each experiment, total RNA was extracted from
105 cells using the RNeasy system (Qiagen, Hilden, Ger-
many). Total RNA was reverse transcribed using random
hexamer primers. For quantitative PCR, the appropriate
primers and FAM-TAMRA labeled probes were purchased
as 20-fold concentrated predeveloped assays from
Applied Biosystems and used according to the instruc-
tions of the manufacturer. 18S rRNA gene was co-ampli-
fied as an internal standard. Data were calculated with the
∆∆ Ct method as described [15].
Measurement of soluble Fas (sFas) in cell culture 
supernatant and cell surface bound Fas
For the detection of sFas in the cell culture supernatants of
the fibroblasts, a commercially available ELISA (Quantik-
ine Assays, R&D Systems, Wiesbaden, Germany) was used
according to the manufacturer's instructions.
The amount of cell-surface-bound Fas was measured by
flow cytometry after staining the fibroblasts with FITC-
labelled anti-Fas/CD95 antibodies (Becton Dickinson).
Statistical analysis
All statistical analyses were performed with SPSS 10.0 for
Windows (SPSS, Chicago, IL). Results were presented as
mean values ± SE. Mean values were compared by Stu-
dent's t-Test. In addition the data were analysed using the
non-parametric Mann-Whitney-U-Test. Differences wereRespiratory Research 2005, 6:37 http://respiratory-research.com/content/6/1/37
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considered to be significant if the p-values were below
0.05 in both tests.
Results
Characterization of lung fibroblasts
The fibroblasts isolated from lung tissue specimens were
characterized with respect to the expression of lineage-
specific marker proteins (Fig. 1A). The majority of the cells
stained with antibodies directed against Thy-1, an antigen
that is specific for fibroblasts. These cells also expressed
the fibroblast specific antigen D7-Fib and the enzyme pro-
lyl-4-hydroxylase, which is involved in collagen synthesis.
Neither CD68, a marker of monocytes/macrophages, nor
CD45, a leukocyte membrane protein, were detected. We
found no significant differences in the phenotypic charac-
teristics of fibroblasts which were derived from different
patient groups.
The matrix production of fibroblasts isolated from fibrotic
(fibrotic fibroblasts, f-fibs) and non-fibrotic lung tissues
(normal fibroblasts, n-fibs) was also analyzed: F-fibs pro-
duced significantly more ECM proteins, including colla-
gen, than n-fibs (Fig. 1B) independent from the
underlying disease.
Resistance to Fas induced apoptosis in lung fibroblasts
Recently we showed that fibroblasts derived from patients
with different inflammatory joint diseases display differ-
ent susceptibilities to FasL-induced apoptosis [14]. Com-
paring fibroblasts derived from human lung tissues, we
applied the same conditions for induction of apoptosis
and found that lung fibroblasts are generally more resist-
ant to FasL-induced apoptosis than synovial fibroblasts
(Fig. 1C). Similar results were found after staurosporin
treatment of fibroblasts (Fig. 1C) and after induction of
apoptosis by anti-Fas antibodies (not shown). The per-
centage of apoptotic cells, as determined by TUNEL stain-
ing, was at the detection limit. Therefore this method
could not be used for the comparison of apoptosis in lung
fibroblasts. On the other hand, we found low but measur-
able apoptosis after quantification of the amount of his-
tone-associated DNA fragments in the cellular
supernatants. Comparison of f-fibs and n-fibs confirmed
that f-fibs were more resistant to FasL-induced apoptosis.
Incubation of the cells with TNF-α  slightly increased the
susceptibility of n-fibs to apoptosis, but it had no affect on
apoptosis in f-fibs (Fig. 1D).
Recently Tanaka et al. have shown that the resistance to
anti-Fas-induced apoptosis in lung fibroblasts is mediated
by the overexpression of the specific inhibitors of apopto-
sis X-chromosome-linked inhibitor of apoptosis (ILP)
and FLICE-like inhibitor protein (FLIP) [16].
Those authors found that suppression of protein synthesis
using cycloheximide decreased the concentration of these
short-lived inhibitory proteins and led to increased sus-
ceptibility to Fas-mediated apoptosis. We used cyclohex-
imide to analyse whether the differences in sensitivity to
FasL-induced apoptosis depended on different expression
levels of short-lived inhibitory proteins. As expected, pre-
incubation of fibroblasts with cycloheximide increased
apoptosis as determined by TUNEL-staining. However,
the percentage of apoptotic cells among f-fibs was still
lower than among n-fibs (Fig. 2), which suggests that
short-lived inhibitory proteins do not contribute to the
difference in apoptosis resistance between n-fibs and f-
fibs. Therefore, other mechanisms are involved in the reg-
ulation of the resistance to FasL-induced apoptosis in f-
fibs.
Expression of Fas
Expression of Fas plays a crucial role in FasL-induced
apoptosis. Therefore, we investigated Fas-mRNA expres-
sion using quantitative RT-PCR analysis. Fas-mRNA levels
were normalized to 18S-ribosomal RNA. Surprisingly, we
found increased expression of Fas-mRNA in f-fibs (Fig.
3A). To determine whether increased Fas mRNA in f-fibs
translates into increased levels of cell surface Fas, we used
flow cytometry to analyze the expression of Fas on the cell
surface of lung fibroblasts. We found that 65 ± 3% (mean
fluorescence intensity 41 ± 5%) of n-fibs and 41 ± 5% of
f-fibs (mean fluorescence intensity 24 ± 2%) expressed Fas
at the cell surface (Fig. 3B, C). Based on these data, we
then determined the concentration of soluble Fas in the
culture supernatant and found an increased concentration
of soluble Fas in the supernatant of f-fibs (Fig. 3D).
Discussion
Lung fibrosis remains a devastating clinical condition
with very limited therapeutic options. A number of exper-
imental approaches have been investigated in clinical tri-
als, including the modulation of key cytokines and
growth factors, and treatment with corticosteroids or
immunosuppressants. In a number of patients, especially
those with UIP, these treatments have little effect on
patient outcome [17-19]. The persistence of fibrotic
lesions, which characterize lung fibrosis and lead to organ
dysfunction, suggests that decreased apoptosis of myofi-
broblasts may play a major role in the pathology of lung
fibrosis.
The present study provides evidence that fibroblasts
derived from lung tissues of patients with lung fibrosis are
characterized by a relative resistance to Fas-mediated
apoptosis. In this context we have shown that the resist-
ance to apoptosis depends not only on the expression of
short-lived intracellular anti-apoptotic proteins, but that
increased production of soluble Fas adds to this process.Respiratory Research 2005, 6:37 http://respiratory-research.com/content/6/1/37
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The resulting long-lived cells may contribute to increased
matrix-deposition, and thus to altered tissue remodeling
in the diseased lung.
In our study we used fibroblasts from patients with differ-
ent fibrotic lung diseases, which were characterized by a
1.6-fold increase in production of extracellular matrix
proteins, particularly collagen. The findings suggest that
these cells retained their fibrotic differentiation state in
short-term culture. Previously, it was shown that lung
fibrosis is characterized by predominant differentiation of
fibroblasts into myofibroblasts [20]. These cells are char-
acterized by increased ECM production. The data concern-
ing apoptosis in these cells are conflicting. Whereas
Lung fibroblasts from patients with fibrotic lung diseases are resistant to apoptosis Figure 1
Lung fibroblasts from patients with fibrotic lung diseases are resistant to apoptosis. A: Characterization of isolated 
fibroblasts using flow cytometry with lineage-specific monoclonal antibodies. Immunoreactivity was detected after staining with 
the fibroblasts specific anti-Thy-1, D7-fib and anti-P-4-H antibodies, but not with anti-CD45 and anti-CD68 antibodies. The 
specificity of the immunostaining (solid line) was tested using irrelevant isotype controls (dotted line). All fibroblasts samples 
were analyzed and representative figures were presented. B: Matrix deposition by isolated fibroblasts as determined by a 
[3H]proline incorporation. Fibroblasts derived from patients with lung fibrosis deposited more extracellular matrix (solid cir-
cles) and collagen (open circles) than non-fibrotic fibroblasts (solid and open squares). C: Increased apoptosis in lung fibroblasts 
(upper panel) compared to synovial fibroblasts (lower panel). Apoptosis was induced by incubation with Fas ligand (rhFasL) and 
measured after TUNEL staining. Lung fibroblasts showed significantly more apoptosis resistance. D: Increased resistance to 
pro-apoptotic signals in fibrotic fibroblasts (square) compared to control fibroblasts (circle). Apoptosis was induced by rhFasL 
after pre-incubation with TNF-alpha. Apoptosis was measured by quantification of histone-bound DNA fragments.
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Resistance to pro-apoptotic signals in fibrotic fibroblasts after incubation with cycloheximide and Fas ligand Figure 2
Resistance to pro-apoptotic signals in fibrotic fibroblasts after incubation with cycloheximide and Fas ligand. A: 
Representative histograms of non-fibrotic (upper panel) and fibrotic fibroblasts (lower panel). The cells were incubated with 
medium, FasL, cycloheximide or FasL+cycloheximide. Only the incubation with FasL and cycloheximide resulted in significant 
amounts of apoptotic cells. B: Fibrotic fibroblasts (circles) showed increased resistance to the induction of apoptosis by FasL 
and cycloheximide in comparison to non-fibrotic fibroblasts (squares). Apoptotic cells were detected by flow cytometry after 
TUNEL staining. The cumulative data of all samples are represented as mean ± SEM, **p < 0.01.
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Ramos and coworkers reported increased spontaneous
apoptosis in fibroblasts obtained from patients with UIP,
[20] TANAKA et al. found a high resistance to Fas-medi-
ated apoptosis in lung fibroblasts [16]. In addition, it was
reported that the apoptosis of myofibroblasts is sup-
pressed by TGF-β 1 [6] and that increasing amounts of
TGF-β 1 are produced by f-fibs [20]. In our experiments we
found very low levels of apoptosis in all the lung fibrob-
lasts investigated. After TUNEL-staining, the spontaneous
amount of apoptotic cells was generally below 2%. This
was similar to the data derived from synovial fibroblasts
[14]. However, in contrast to synovial fibroblasts, apopto-
sis remained low after incubation of lung fibroblasts with
FasL, anti-Fas antibodies or staurosporin. The data are
consistent with the findings of Tanaka et al. who investi-
gated normal lung fibroblasts and the lung fibroblast cell
Expression of soluble and surface-bound Fas in normal and fibrotic lung fibroblasts Figure 3
Expression of soluble and surface-bound Fas in normal and fibrotic lung fibroblasts. A: Increased levels of Fas-
mRNA were found in fibrotic fibroblasts (circles) in comparison to non-fibrotic fibroblasts (squares). Fas-mRNA levels were 
measured using quantitative RT-PCR. B: Fas surface expression on isolated fibroblasts. Representative histograms of Fas-immu-
nostaining on isolated fibroblasts (solid line). The specificity of the immunostaining was shown using irrelevant isotype-matched 
control antibodies (dotted line). Non-fibrotic fibroblasts (upper panel) expressed more surface bound Fas than fibrotic fibrob-
lasts (lower panel). C: Cumulative data of all analysed samples showed that the percentages of Fas-positive cells (left panel) as 
well as the mean fluorescence intensities (right panel) were lower in fibrotic fibroblasts (circles) compared to non-fibrotic 
fibroblasts (squares). The results are represented as mean ± SEM. D: Increased concentration of soluble Fas in the supernatant 
of fibrotic fibroblasts (circles) in comparison to non-fibrotic fibroblasts (squares). The concentration of soluble Fas was meas-
ured by ELISA. The results are represented as mean ± SEM, *p < 0.05, **p < 0.01.
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line WI-38 [16]. Only the application of very sensitive
detection systems allowed us to quantify apoptosis in
these cells. Using these assays we were able to demon-
strate that f-fibs are more resistant to Fas-mediated apop-
tosis than n-fibs. However, we found no direct correlation
between the matrix production of isolated fibroblasts and
the amount of apoptosis.
Apart from interfering with receptor activation at the cell-
surface, apoptosis can also be blocked by intracellular
anti-apoptotic proteins. For example FLICE-like inhibi-
tory proteins (FLIPs) can prevent the recruitment and acti-
vation of caspase 8 (FLICE) to the Fas-associated protein
with death domain (FADD), and thus inhibit the forma-
tion of the death inducing signaling complex (DISC). In
addition, anti-apoptotic members of the bcl-family, e.g.,
Bcl-2, MCL-1 and A1, prevent the mitochondrial cyto-
chrome c release. Recently, the inhibitor of apoptosis
(IAP) family of genes was identified [21]. The X-linked
IAP (ILP) suppresses apoptosis by direct inhibition of cas-
pase 3. In a variety of experimental systems it has been
shown that the overexpression of these anti-apoptotic
proteins results in resistance to pro-apoptotic signals [21-
23]. Therefore, it was tempting to speculate that a differ-
ential expression of these anti-apoptotic proteins in n-fibs
and f-fibs may cause the resistance to Fas-mediated apop-
tosis in lung fibroblasts.
Anti-apoptotic bcl-2 proteins and IAPs are characterized
by a very short half-life. [22,24]. Cycloheximide, which
blocks protein synthesis, was shown to decrease the con-
centration of ILP and FLICE in human lung fibroblasts on
the one hand, and to increase the sensitivity of these cells
to Fas-mediated apoptosis on the other hand [16]. Our
experiments showed that short-lived anti-apoptotic pro-
teins are generally involved in the apoptosis resistance of
lung fibroblasts. However, they did not contribute to the
different susceptibilities of n-fibs and f-fibs. Finally, we
found a difference in the Fas-mRNA levels. F-fibs had
higher Fas-mRNA levels with lower levels of surface-
bound Fas-receptor than n-fibs. At the same time, f-fibs
exhibited higher expression of soluble Fas, which exerts
an anti-apoptotic function [25]. It has been shown that
soluble Fas is produced as an alternatively spliced variant
of Fas. On the other hand increased soluble Fas concentra-
tions were found in patients with rheumatoid arthritis
and the release was correlated to increased activities of
matrix metallo proteases [26]. We have recently shown
that fibrotic fibroblasts expressed increased amounts of
the potent protease cathepsin K [9]. An important role of
matrix metalloproteases was shown by other groups
[27,28]. In summary the release of soluble Fas can be reg-
ulated by different mechanisms. Part of them is activated
in fibrotic fibroblasts.
From these data, we conclude that the increased resistance
to pro-apoptotic signals in lung fibroblasts obtained from
patients with fibrosis is mediated at least in part by
increased amounts of soluble Fas.
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